From: Will bevacizumab biosimilars impact the value of systemic therapy in gynecologic cancers?
Citation | Treatment regimen | Total/Incremental costs (USD) | Effectiveness/Incremental effectiveness | ICER | Key findings |
---|---|---|---|---|---|
Cohn et al. 2011 | PAC + CAR | 2.5 milliona | 10.3 monthsb | Referent | Addition of BEV and maintenance BEV was not cost-effective |
PAC + CAR + BEV | 21.4 milliona | 11.2 monthsb | USD479,712 per PFLY gained | ||
(PAC + CAR + BEV) + maintenance BEV | 78.3 milliona | 14.1 monthsb | USD401,088 per PFLY gained | ||
Barnett et al. 2013 | PAC + CAR PAC + CAR + BEV PAC + CAR + BEV for high-risk patients | 6220c 20,751c 56,351c | 2.80d 2.89d 2.88d | Referent USD168,610 per QALY Dominated | Use of BEV with standard first-line taxane was not cost-effective in stage III/IV ovarian cancer. May be suitable in high-risk patients although ICER exceeded thresholds |
Chan et al. 2014 | PAC + CAR | 535e | 10.5b | Referent | For high-risk, advanced ovarian cancer patients, ICER was almost USD170,000 per life-year saved |
PAC + CAR + BEV plus maintenance BEV | 3760 (3225 for maintenance)e | 15.9b | USD167,771 per LYG |